title: PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study.
abstract: Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance. Several reports have clearly demonstrated that PPARgamma ligands could inhibit colorectal cancer cell growth and induce apoptosis. Meanwhile, aberrant crypt foci (ACF) have come to be established as a biomarker of the risk of CRC in azoxymethane-treated mice and rats. In humans, ACF can be detected using magnifying colonoscopy. Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period. In this clinical study, we investigated the chemopreventive effect of pioglitazone on the development of human ACF as a surrogate marker of CRC. Twenty-nine patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15 mg/day) group, and ACF and adenoma were examined before and after 1-month treatment. The number of ACF was significantly decreased (5.8 +/- 1.1 to 3.3 +/- 2.3) after 1 month of pioglitazone treatment, however, there was no significant change in the number of crypts/ACF or in the number and size of adenomas. Pioglitazone may have a clinical application as a cancer-preventive drug. This investigation is just a pilot study, therefore, further clinical studies are needed to show that the PPARgamma ligand may be a promising candidate as a chemopreventive agent for colorectal carcinogenesis.
authors.affiliation: Gastroenterology Division, Graduate School of Medicine, Yokohama City University, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, 236-0004, Japan.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Hosono
authors.forename: Takashi
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Michiko
authors.initials: M
authors.lastname: Sugiyama
authors.forename: Eiji
authors.initials: E
authors.lastname: Sakai
authors.forename: Hiroki
authors.initials: H
authors.lastname: Endo
authors.forename: Shin
authors.initials: S
authors.lastname: Maeda
authors.forename: Katherine L
authors.initials: KL
authors.lastname: Schaefer
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakagama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
references.citation: Carcinogenesis. 1992 Sep;13(9):1509-12
references.pmid: 1394832
references.citation: N Engl J Med. 1998 Oct 29;339(18):1277-84
references.pmid: 9791143
references.citation: J Am Coll Nutr. 2009 Dec;28(6):678-86
references.pmid: 20516268
references.citation: Gastroenterology. 2007 Aug;133(2):393-402
references.pmid: 17681160
references.citation: Int J Cancer. 2008 Sep 1;123(5):991-7
references.pmid: 18546290
references.citation: Mol Cell. 1998 Feb;1(3):465-70
references.pmid: 9660931
references.citation: J Natl Cancer Inst. 2009 Feb 18;101(4):256-66
references.pmid: 19211452
references.citation: Br J Cancer. 2003 Oct 20;89(8):1409-12
references.pmid: 14562008
references.citation: Cancer Lett. 1987 Oct 30;37(2):147-51
references.pmid: 3677050
references.citation: Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41
references.pmid: 8990192
references.citation: N Engl J Med. 2005 Mar 17;352(11):1092-102
references.pmid: 15713943
references.citation: PPAR Res. 2008;2008:785405
references.pmid: 18509498
references.citation: Gastroenterology. 2003 Feb;124(2):361-7
references.pmid: 12557142
references.citation: Cancer Sci. 2003 Nov;94(11):960-4
references.pmid: 14611672
references.citation: J Lab Clin Med. 2002 Jul;140(1):17-26
references.pmid: 12080324
references.citation: Int J Oncol. 2001 Sep;19(3):465-71
references.pmid: 11494023
references.citation: Cancer J. 2002 Sep-Oct;8(5):395-9
references.pmid: 12416897
references.citation: Br J Cancer. 2000 Nov;83(10):1394-400
references.pmid: 11044367
references.citation: Cancer Res. 2000 Feb 15;60(4):1129-38
references.pmid: 10706135
references.citation: Cancer Metastasis Rev. 2003 Mar;22(1):67-82
references.pmid: 12716038
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):906-14
references.pmid: 12223437
references.citation: Cancer. 2009 Dec 15;115(24):5662-71
references.pmid: 19827153
references.citation: J Pharmacol Sci. 2008 Apr;106(4):627-38
references.pmid: 18391483
references.citation: Ann Oncol. 2003;14 Suppl 2:ii3-5
references.pmid: 12810450
references.citation: Gut. 2002 May;50(5):658-64
references.pmid: 11950812
references.citation: Jpn J Cancer Res. 1999 Jan;90(1):75-80
references.pmid: 10076568
references.citation: FEBS Lett. 1999 Jul 16;455(1-2):135-9
references.pmid: 10428487
references.citation: Carcinogenesis. 1998 Jan;19(1):49-53
references.pmid: 9472692
references.citation: J Clin Endocrinol Metab. 2001 May;86(5):2170-7
references.pmid: 11344222
references.citation: Postgrad Med J. 2007 Jun;83(980):414-9
references.pmid: 17551074
references.citation: Int J Cancer. 2006 Nov 15;119(10):2339-46
references.pmid: 16858678
references.citation: Neoplasia. 1999 Oct;1(4):330-9
references.pmid: 10935488
references.citation: Biochem Biophys Res Commun. 2001 Sep 21;287(2):522-9
references.pmid: 11554760